Breaking News

Scinai Launches U.S. CDMO to Meet Growing Demand

Aims to serve U.S.-based early-stage biotech companies by providing the required CDMO services that are currently in short supply.

Author Image

By: Charlie Sternberg

Associate Editor

Scinai Immunotherapeutics Ltd., a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and providing CDMO services, has established a U.S.-based subsidiary for its Contract Development and Manufacturing Services, which will operate under the name Scinai Bioservices Inc.   Scinai’s new U.S. subsidiary, Scinai Bioservices Inc., aims to serve U.S.-based early-stage biotech companies by providing the required CDMO services that are current...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters